Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Antipsychotic effects of N-desmethylclozapine on sensorimotor gating function in rats--possible involvement of activation of M(1) muscarinic receptors.

Maehara S, Satow A, Hikichi H, Ohta H.

Eur J Pharmacol. 2011 Sep 30;667(1-3):242-9. doi: 10.1016/j.ejphar.2011.05.063. Epub 2011 Jun 2.

PMID:
21658379
2.

Effect of CFMTI, an allosteric metabotropic glutamate receptor 1 antagonist with antipsychotic activity, on Fos expression in regions of the brain related to schizophrenia.

Suzuki G, Satow A, Ohta H.

Neuroscience. 2010 Jul 14;168(3):787-96. doi: 10.1016/j.neuroscience.2010.04.016. Epub 2010 Apr 18.

PMID:
20399255
3.

Pharmacological effects of metabotropic glutamate receptor ligands on prepulse inhibition in DBA/2J mice.

Hikichi H, Nishino M, Fukushima M, Satow A, Maehara S, Kawamoto H, Ohta H.

Eur J Pharmacol. 2010 Aug 10;639(1-3):99-105. doi: 10.1016/j.ejphar.2010.03.046. Epub 2010 Apr 2.

PMID:
20371235
4.

Effects of a novel metabotropic glutamate receptor 7 negative allosteric modulator, 6-(4-methoxyphenyl)-5-methyl-3-pyridin-4-ylisoxazonolo[4,5-c]pyridin-4(5H)-one (MMPIP), on the central nervous system in rodents.

Hikichi H, Murai T, Okuda S, Maehara S, Satow A, Ise S, Nishino M, Suzuki G, Takehana H, Hata M, Ohta H.

Eur J Pharmacol. 2010 Aug 10;639(1-3):106-14. doi: 10.1016/j.ejphar.2009.08.047. Epub 2010 Apr 2.

PMID:
20371227
5.

Discovery and biological profile of isoindolinone derivatives as novel metabotropic glutamate receptor 1 antagonists: a potential treatment for psychotic disorders.

Ito S, Hirata Y, Nagatomi Y, Satoh A, Suzuki G, Kimura T, Satow A, Maehara S, Hikichi H, Hata M, Ohta H, Kawamoto H.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5310-3. doi: 10.1016/j.bmcl.2009.07.145. Epub 2009 Aug 3.

PMID:
19692242
6.

Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist.

Satoh A, Nagatomi Y, Hirata Y, Ito S, Suzuki G, Kimura T, Maehara S, Hikichi H, Satow A, Hata M, Ohta H, Kawamoto H.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5464-8. doi: 10.1016/j.bmcl.2009.07.097. Epub 2009 Jul 23.

PMID:
19674894
7.

Correlation of receptor occupancy of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse brain with in vivo activity of allosteric mGluR1 antagonists.

Suzuki G, Kawagoe-Takaki H, Inoue T, Kimura T, Hikichi H, Murai T, Satow A, Hata M, Maehara S, Ito S, Kawamoto H, Ozaki S, Ohta H.

J Pharmacol Sci. 2009 Jul;110(3):315-25. Epub 2009 Jun 19.

8.

Quantification of mouse pulmonary cancer models by microcomputed tomography imaging.

Fushiki H, Kanoh-Azuma T, Katoh M, Kawabata K, Jiang J, Tsuchiya N, Satow A, Tamai Y, Hayakawa Y.

Cancer Sci. 2009 Aug;100(8):1544-9. doi: 10.1111/j.1349-7006.2009.01199.x. Epub 2009 May 13.

9.

Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one.

Satow A, Suzuki G, Maehara S, Hikichi H, Murai T, Murai T, Kawagoe-Takaki H, Hata M, Ito S, Ozaki S, Kawamoto H, Ohta H.

J Pharmacol Exp Ther. 2009 Jul;330(1):179-90. doi: 10.1124/jpet.109.151118. Epub 2009 Apr 9.

10.

Discovery and biological profile of 4-(1-aryltriazol-4-yl)-tetrahydropyridines as an orally active new class of metabotropic glutamate receptor 1 antagonist.

Ito S, Satoh A, Nagatomi Y, Hirata Y, Suzuki G, Kimura T, Satow A, Maehara S, Hikichi H, Hata M, Kawamoto H, Ohta H.

Bioorg Med Chem. 2008 Nov 15;16(22):9817-29. doi: 10.1016/j.bmc.2008.09.060. Epub 2008 Sep 30.

PMID:
18849168
11.

Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia.

Maehara S, Hikichi H, Satow A, Okuda S, Ohta H.

Pharmacol Biochem Behav. 2008 Nov;91(1):140-9. doi: 10.1016/j.pbb.2008.06.023. Epub 2008 Jul 2.

PMID:
18651995
13.

Face-washing behavior induced by the group I metabotropic glutamate receptor agonist (S)-3,5-DHPG in mice is mediated by mGlu1 receptor.

Hikichi H, Iwahori Y, Murai T, Maehara S, Satow A, Ohta H.

Eur J Pharmacol. 2008 May 31;586(1-3):212-6. doi: 10.1016/j.ejphar.2008.02.061. Epub 2008 Feb 29.

PMID:
18378225
14.

Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).

Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H.

J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. Epub 2007 Mar 14.

15.

The objective measurement of pain using a motor-performance task.

Taniguchi S, Satow A.

Ergonomics. 1991 Sep;34(9):1215-20.

PMID:
1743179
16.

Japanese version of the MPQ and pentagon profile illustrated perceptual characteristics of pain.

Satow A, Nakatani K, Taniguchi S.

Pain. 1989 Apr;37(1):125-6. No abstract available.

PMID:
2726273
17.

The development of a motor performance method for the measurement of pain.

Satow A, Taniguchi S.

Ergonomics. 1989 Mar;32(3):307-16.

PMID:
2737180
18.
19.
20.
22.

[Equal-sensation contours and a threshold curve for low-frequency vibrotactile stimuli on the glabrous skin of the human hand].

Fukuda H, Satow A, Miyaoka T.

Shinrigaku Kenkyu. 1982 Aug;53(3):169-73. Japanese.

PMID:
7176233
23.

Supplemental Content

Support Center